There were no clinically significant differences while in the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when made use of concomitantly with finerenone. Various doses of 40 mg finerenone the moment-day-to-day had no clinically relevant impact on AUC o